Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

NCT00718237 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

762

Enrollment

INDUSTRY

Sponsor class

Conditions

Rotavirus
Gastroenteritis

Interventions

BIOLOGICAL: Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
BIOLOGICAL: Comparator: Comparator: Placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC